CAS NO: | 1883545-51-4 |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
生物活性 | AZD5582 dihydrochloride is an antagonist of the inhibitor ofapoptosisproteins (IAPs), which binds to the BIR3 domainscIAP1, cIAP2, andXIAPwithIC50s of 15, 21, and 15 nM, respectively. AZD5582 inducesapoptosis[1]. | ||||||||||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||||||||||
体外研究 (In Vitro) | AZD5582 (20 nM; 48 hours) inhibits cell viability by cooperation with IFNγ or viral double-stranded RNA (dsRNA) in H1975 NSCLC cells[2].AZD5582 (20 nM; 17 or 25 hours) downregulates cIAP-1, activates RIPK1 (upstream regulator of caspase-8), and triggers the activation of extrinsic (caspase-8) and intrinsic (caspase-9) apoptosis pathways, causing the cleavage of caspase-3 and caspase-7[2].AZD5582 (20 nM; 48 hours) involves in apoptosis due to induction of cell death and active caspase-3/8 activities by AZD5582 and IFNγ co-treatment in HCC827 NSCLC cells[2]. Cell Viability Assay[2]
Apoptosis Analysis[2]
Western Blot Analysis[2]
| ||||||||||||||||||||||||
体内研究 (In Vivo) | AZD5582 (intravenous injection; 0.1-3.0 mg/kg; once a week; 2 weeks) causes degradation of cIAP1 and caspase 3 cleavage in tumor cells, and after a two-week treatment, the tumors largely resolved; when the mice are given a medium dose (0.5 mg/kg) of AZD5582, cIAP1 degrades after administration, but it takes a while time to reach apoptosis-inducing effect[1].
| ||||||||||||||||||||||||
分子量 | 1088.21 | ||||||||||||||||||||||||
性状 | Solid | ||||||||||||||||||||||||
Formula | C58H80Cl2N8O8 | ||||||||||||||||||||||||
CAS 号 | 1883545-51-4 | ||||||||||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||||||||||
储存方式 | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) | ||||||||||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 50 mg/mL(45.95 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|